Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hyperlipoproteinemias

  Free Subscription


Articles published in Am J Cardiol

Retrieve available abstracts of 51 articles:
HTML format



Single Articles


    March 2021
  1. ELGENDY IY, Kolte D, Mansour MK, Sakhuja R, et al
    Incidence, Predictors, and Outcomes of Thrombotic Events in Hospitalized Patients With Viral Pneumonia.
    Am J Cardiol. 2021;143:164-165.
    PubMed    


    January 2021
  2. ZHANG R, Xie J, Zhou J, Xu L, et al
    Supravalvular Aortic Stenosis and the Risk of Premature Death among Patients with Homozygous Familial Hypercholesterolemia.
    Am J Cardiol. 2021 Jan 14. pii: S0002-9149(21)00037.
    PubMed     Abstract available


    November 2020
  3. KURIHARA O, Kim HO, Russo M, Araki M, et al
    Relation of Low-Density Lipoprotein Cholesterol Level to Plaque Rupture.
    Am J Cardiol. 2020;134:48-54.
    PubMed     Abstract available


    October 2020
  4. ABUGROUN A, Taha A, Abdel-Rahman M, Volgman AS, et al
    Economic Impact of Atrial Fibrillation on Hospitalization Outcomes of Acute Heart Failure in the United States.
    Am J Cardiol. 2020 Oct 16. pii: S0002-9149(20)31119.
    PubMed    


    September 2020
  5. TAYLAN C, Driemeyer J, Schmitt CP, Pape L, et al
    Cardiovascular Outcome of Pediatric Patients With Bi-Allelic (Homozygous) Familial Hypercholesterolemia Before and After Initiation of Multimodal Lipid Lowering Therapy Including Lipoprotein Apheresis.
    Am J Cardiol. 2020 Sep 15. pii: S0002-9149(20)30952.
    PubMed     Abstract available


    August 2020
  6. KHAN SA, Naz A, Qamar Masood M, Shah R, et al
    Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
    Am J Cardiol. 2020 Aug 15. pii: S0002-9149(20)30866.
    PubMed     Abstract available


  7. VOLIS I, Saliba W, Jaffe R, Eitan A, et al
    Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease.
    Am J Cardiol. 2020;128:28-34.
    PubMed     Abstract available


  8. YE Q, Svatikova A, Meeusen JW, Kludtke EL, et al
    Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels.
    Am J Cardiol. 2020;128:163-167.
    PubMed     Abstract available


    July 2020
  9. KONG NW, Bavishi A, Amaral AP, Tibrewala A, et al
    Risk Differences in Secondary Prevention Patients Who Present With Acute Coronary Syndrome and Implications of Guideline-Directed Cholesterol Management.
    Am J Cardiol. 2020 Jul 24. pii: S0002-9149(20)30773.
    PubMed     Abstract available


  10. EID WE, Sapp EH, McCreless T, Nolan JR, et al
    Prevalence and Characteristics of Patients With Primary Severe Hypercholesterolemia in a Multidisciplinary Healthcare System.
    Am J Cardiol. 2020 Jul 12. pii: S0002-9149(20)30676.
    PubMed     Abstract available


    June 2020
  11. ASBEUTAH AAA, Asbeutah SA, Abu-Assi MA
    A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Bempedoic Acid.
    Am J Cardiol. 2020 Jun 30. pii: S0002-9149(20)30635.
    PubMed    


  12. GUPTA R, Desai R, Gupta N
    Reply to "Non-vitamin K antagonist oral anticoagulants for atrial fibrillation in obese patients".
    Am J Cardiol. 2020 Jun 11. pii: S0002-9149(20)30564.
    PubMed    


  13. FABIJANIC D, Luksic B, Ljubkovic M
    Statins in primary prevention of cardiovascular disease - should we start while young and healthy?
    Am J Cardiol. 2020 Jun 10. pii: S0002-9149(20)30562.
    PubMed    


    May 2020
  14. ASBEUTAH AAA, Asbeutah SA, Abu-Assi MA
    A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran.
    Am J Cardiol. 2020 May 21. pii: S0002-9149(20)30500.
    PubMed    


  15. XU L, Wen W, Yang Y, Xie J, et al
    Features of Sitosterolemia in Children.
    Am J Cardiol. 2020;125:1312-1316.
    PubMed     Abstract available


    March 2020
  16. JIA X, Ramsey DJ, Rifai MA, Ahmed ST, et al
    Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System).
    Am J Cardiol. 2020;125:874-879.
    PubMed     Abstract available


  17. RASKIND-HOOD C, Saraf A, Riehle-Colarusso T, Glidewell J, et al
    Assessing Pregnancy, Gestational Complications, and Co-morbidities in Women With Congenital Heart Defects (Data from ICD-9-CM Codes in 3 US Surveillance Sites).
    Am J Cardiol. 2020;125:812-819.
    PubMed     Abstract available


    January 2020
  18. KOSTIS JB, Giakoumis M, Zinonos S, Cabrera J, et al
    Meta-Analysis of Usefulness of Treatment of Hypercholesterolemia With Statins for Primary Prevention in Patients Older Than 75 Years.
    Am J Cardiol. 2020 Jan 28. pii: S0002-9149(20)30061.
    PubMed     Abstract available


    December 2019
  19. KREMPF M, Hopkins PN, Bruckert E, Lee S, et al
    Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.
    Am J Cardiol. 2019 Dec 27. pii: S0002-9149(19)31497.
    PubMed     Abstract available


    September 2019
  20. GAUDET D, Durst R, Lepor N, Bakker-Arkema R, et al
    Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
    Am J Cardiol. 2019 Sep 26. pii: S0002-9149(19)31048.
    PubMed     Abstract available


  21. MILLER M, Ballantyne CM, Bays HE, Granowitz C, et al
    Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
    Am J Cardiol. 2019;124:696-701.
    PubMed     Abstract available


    August 2019
  22. RANARD LS, Mallah WE, Awerbach JD, Abernethy A, et al
    Impact of Pulmonary Hypertension on Survival Following Device Closure of Atrial Septal Defects.
    Am J Cardiol. 2019 Aug 7. pii: S0002-9149(19)30873.
    PubMed     Abstract available


  23. ITOH H, Kaneko H, Kiriyama H, Yoshida Y, et al
    Relation between the Updated Blood Pressure Classification according to the American College of Cardiology/American Heart Association Guidelines and Carotid Intima-Media Thickness.
    Am J Cardiol. 2019;124:396-401.
    PubMed     Abstract available


    July 2019
  24. KRYSIAK R, Kowalcze K, Okopien B
    Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
    Am J Cardiol. 2019 Jul 23. pii: S0002-9149(19)30814.
    PubMed     Abstract available


    June 2019
  25. KIM CY, Lee JH, Jang SY, Bae MH, et al
    Usefulness of Calculation of Cardiovascular Risk Factors to Predict Outcomes in Patients With Acute Myocardial Infarction.
    Am J Cardiol. 2019 Jun 25. pii: S0002-9149(19)30710.
    PubMed     Abstract available


  26. LIU X, Yang Y, Kang F, Li J, et al
    Cardiovascular Disease Risk Across a Spectrum of Adverse Plasma Lipid Combinations by Gender and Glycemic Status.
    Am J Cardiol. 2019 Jun 6. pii: S0002-9149(19)30638.
    PubMed     Abstract available


    November 2018
  27. CICERO AFG, Fogacci F, Bove M, Giovannini M, et al
    Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease.
    Am J Cardiol. 2018 Nov 23. pii: S0002-9149(18)32099.
    PubMed     Abstract available


    August 2018
  28. BALLANTYNE CM, Bhatt DL, Cannon CP, Fazio S, et al
    Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.
    Am J Cardiol. 2018 Aug 16. pii: S0002-9149(18)31653.
    PubMed     Abstract available


    July 2018
  29. NICHOLS GA, Philip S, Reynolds K, Granowitz CB, et al
    Comparison of Medical Care Utilization and Costs Among Patients With Statin-Controlled Low-Density Lipoprotein Cholesterol With Versus Without Hypertriglyceridemia.
    Am J Cardiol. 2018 Jul 5. pii: S0002-9149(18)31321.
    PubMed     Abstract available


    March 2018
  30. BLONDHEIM DS, Kleiner-Shochat M, Asif A, Kazatsker M, et al
    Characteristics, Management, and Outcome of Transient ST-elevation Versus Persistent ST-elevation and Non-ST-elevation Myocardial Infarction.
    Am J Cardiol. 2018 Mar 12. pii: S0002-9149(18)30265.
    PubMed     Abstract available


    February 2018
  31. KARALIS DG, Mallya UG, Ghannam AF, Elassal J, et al
    Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Am J Cardiol. 2018 Feb 12. pii: S0002-9149(18)30185.
    PubMed     Abstract available


  32. MCCULLOUGH PA, Ballantyne CM, Sanganalmath SK, Langslet G, et al
    Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    Am J Cardiol. 2018 Feb 2. pii: S0002-9149(18)30093.
    PubMed     Abstract available


    September 2017
  33. EL SHAHAWY M, Cannon CP, Blom DJ, McKenney JM, et al
    Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).
    Am J Cardiol. 2017;120:931-939.
    PubMed     Abstract available


    August 2017
  34. TADA H, Kawashiri MA, Okada H, Nakahashi T, et al
    Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia.
    Am J Cardiol. 2017 Aug 30. pii: S0002-9149(17)31382.
    PubMed     Abstract available


    July 2017
  35. SATTAR N, Toth PP, Blom DJ, Koren MJ, et al
    Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.
    Am J Cardiol. 2017 Jul 31. pii: S0002-9149(17)31220.
    PubMed     Abstract available


    April 2017
  36. BALLANTYNE CM, Shah S, Sapre A, Ashraf TB, et al
    A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Am J Cardiol. 2017 Apr 12. pii: S0002-9149(17)30626.
    PubMed     Abstract available


    February 2017
  37. KOSMIDOU I, Redfors B, Dordi R, Dizon JM, et al
    Incidence, Predictors, and Outcomes of High-Grade Atrioventricular Block in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial).
    Am J Cardiol. 2017 Feb 16. pii: S0002-9149(17)30118.
    PubMed     Abstract available


  38. MOSCA L, Ballantyne CM, Bays HE, Guyton JR, et al
    Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
    Am J Cardiol. 2017;119:397-403.
    PubMed     Abstract available


    January 2017
  39. ZAFRIR B, Jaffe R, Rubinshtein R, Karkabi B, et al
    Impact of Diabetes Mellitus on Long-Term Mortality in Patients Presenting for Coronary Angiography.
    Am J Cardiol. 2017 Jan 25. pii: S0002-9149(17)30049.
    PubMed     Abstract available


  40. GAUDET D, Watts GF, Robinson JG, Minini P, et al
    Effect of Alirocumab on Lipoprotein(a) Over >/=1.5 Years (from the Phase 3 ODYSSEY Program).
    Am J Cardiol. 2017;119:40-46.
    PubMed     Abstract available


    December 2016
  41. JONES PH, Bays HE, Chaudhari U, Pordy R, et al
    Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.
    Am J Cardiol. 2016;118:1805-1811.
    PubMed     Abstract available


  42. PEREZ-CALAHORRA S, Sanchez-Hernandez RM, Plana N, Marco-Benedi V, et al
    Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
    Am J Cardiol. 2016 Dec 2. pii: S0002-9149(16)31894.
    PubMed     Abstract available


    November 2016
  43. NICHOLS GA, Reynolds K, Olufade T, Kimes TM, et al
    Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
    Am J Cardiol. 2016 Nov 4. pii: S0002-9149(16)31740.
    PubMed     Abstract available


  44. BALLANTYNE CM, Shah S, Kher U, Hunter JA, et al
    Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Am J Cardiol. 2016 Nov 1. pii: S0002-9149(16)31743.
    PubMed     Abstract available


    September 2016
  45. BLAHA MJ
    Personalizing Treatment: Between Primary and Secondary Prevention.
    Am J Cardiol. 2016;118.
    PubMed     Abstract available


  46. TOTH PP
    Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction.
    Am J Cardiol. 2016;118.
    PubMed     Abstract available


  47. MIEDEMA MD, Virani SS
    Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies.
    Am J Cardiol. 2016;118.
    PubMed     Abstract available


  48. TOTH PP, Catapano AL, Farnier M, Foody J, et al
    Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
    Am J Cardiol. 2016 Sep 13. pii: S0002-9149(16)31478.
    PubMed     Abstract available


  49. KONISHI H, Miyauchi K, Shitara J, Endo H, et al
    Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
    Am J Cardiol. 2016 Sep 13. pii: S0002-9149(16)31474.
    PubMed     Abstract available


    July 2016
  50. TERAMOTO T, Kobayashi M, Uno K, Takagi Y, et al
    Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies).
    Am J Cardiol. 2016;118:56-63.
    PubMed     Abstract available


    May 2016
  51. HECHT EM, Arheart KL, Lee DJ, Hennekens CH, et al
    Interrelation of Cadmium, Smoking, and Cardiovascular Disease (from the National Health and Nutrition Examination Survey).
    Am J Cardiol. 2016 May 4. pii: S0002-9149(16)30560.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: